WebJan 1, 2024 · Next ». (a) A father-child relationship is established by an adjudication of a man's parentage, by operation of subsection (e) of this section, or by an unrebutted … WebNov 1, 2024 · (PDF) 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA …
Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma …
WebNOTE: Patients who are enrolled into the PD-L1 amplification cohort do not have to qualify for one of the histologically-defined cohorts in Section 18.1. a. Patients are eligible under ONE of the following criteria: ... participate in EAY131 “NCI-MATCH” to register to S1609. OR. ii. FOR PATIENTS WITH PD-L1 AMPLIFICATION (Cohort #50) ONLY ... WebAug 1, 2024 · The SWONG S1609 study enrolled patients with metastatic or unresectable angiosarcoma. All patients received a combination of ipilimumab and nivolumab, and the trial results demonstrated a 25% ORR... herisau spital gynäkologie
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 …
WebNov 1, 2024 · (PDF) 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in... WebMulticenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) Journal for ImmunoTherapy of Cancer Home Archive Volume 9, Issue 8 Email alerts PDF PDF + Supplementary Material XML WebWe report results for angiosarcoma treated with ipilimumab and nivolumab as a cohort of an ongoing rare cancer study. METHODS: This is a prospective, open-label, multicenter phase II clinical trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) for metastatic or unresectable angiosarcoma. herisau spital